Get started

LLY

"LLY's Bear Market Mode ON | Crash Incoming"“ LLY is gearing up for a sharp correction down to the $35–$17 zone — a critical reset that could flush out weak hands before the next explosive bull run. Stay sharp, this is where big opportunities form. ⚠️ 🔥 Summary: Eli Lilly (LLY) looks ready for a major market reset after completing a historic five-wave climb. This could be the start of a long-term corrective Wave 2 , potentially wiping out years of gains before the next explosive super-cycle takes off. The bull run isn’t over — but it’s taking a serious pause. ⚠️📉 🌊 Wave Theory Outlook LLY’s multi-decade Elliott structure shows a completed Cycle Wave 1 peaking near the 2.618 extension zone around $1029. Historically, such extensions often mark exhaustion. Next comes Wave 2 , which could retrace deep into the $35–$17 zone (the 0.618–0.786 Fibonacci region and prior structural base). Expect a complex W-X-Y pattern , shaking weak hands before a powerful Wave 3 bull expansion later this decade. 📉 Price Action & Smart Money Context The chart shows exhaustion wicks, momentum divergence, and slowing volume — classic signs of distribution . Smart money is likely off-loading near the highs , preparing to reload at discount levels once liquidity below 2020–2022 lows is taken. Expect liquidity sweeps, imbalance fills, and a long-term accumulation base forming near the orange demand zone before the next breakout. 💰 Fundamental Alignment Despite incredible fundamentals — obesity and diabetes drug leadership, global demand growth, and innovation — valuation gravity always returns . A deep correction would align price with sustainable earnings and provide institutional re-entry opportunities at fair value. 🧠 Traders , "the charts are whispering — a major LLY correction is loading. Our projections highlight the $35–$17 zone as the key accumulation region before the next super-cycle. Stay alert, plan your levels, and don’t fight the wave. 🌊📉 Where do you think LLY bottoms out? Share your thoughts below 👇” — Team FIBCOS #LLY #EliLilly #BearMarket #Correction #WaveTheory #SmartMoney #ElliottWave #Fibcos #TechnicalAnalysis #PriceAction #Investing #PharmaStocks #StockMarket #MarketCycle #ChartAnalysis #Bearish #Wave2 #TradingView #StockAlert #MarketReset
NYSE:LLYShort
by fibcos
8
LLY - Beware the MotherbarTaking a closer look at the Eli Lilly chart and noticed that there is a box setup forming on the daily time frame. Specifically this box is the product of a mother bar. If you take a look the last 4 daily candles have more or less traded within the body of the XXL green candle on the left. I would be mindful of this mother bar/box in the coming week. Don't get too bulllish at the top or two bearish at the bottom. I suggest also taking a look at SPY's chart as there is a similar pattern forming, albeit a much more defined motherbar. A look above and fail of $824 could make a great short, or a look below and fail of $763(A+) or $773(B+) is a great long. The trendline also sits near that low so if the LBAF plays out that is another supporting confluence for this trade.
NYSE:LLY
by The_Villain_777
2
ELI LILLY COMPANY - STOCK REPORTExecutive Summary Eli Lilly and Company (LLY) has delivered strong revenue and profit growth driven by blockbuster GLP‑1 therapies (Mounjaro, Zepbound) and continued pipeline progress in oncology and cardiometabolic indications. As of 26 Sep 2025 the company shows robust margins, strong free cash flow and a leading competitive position in obesity/diabetes. Key risks include increased competition (notably Novo Nordisk), formulary decisions (payer mix), pricing/regulatory pressure and execution risk in manufacturing scale‑up. Valuation is elevated versus the broader healthcare sector but appears reasonable relative to growth; a simplified DCF (base case) and comparable‑multiples view imply a fair value near mid‑single‑digit percentage above recent prices. Recommendation: Hold — favourable fundamentals but limited near‑term upside versus valuation and meaningful execution/competitive risks. 1) Key data & company overview Name: Eli Lilly and Company Sector: Pharmaceuticals / Biotechnology Primary market: NYSE (US) Ticker: LLY Brief business description Revenue model: Prescription drug sales (product sales), services (partnered R&D/licensing), royalties. Principal products: Mounjaro (tirzepatide) — T2D/weight management; Zepbound (semaglutide for weight loss comp’d), Trulicity, Humalog (insulin legacy portfolio), oncology candidates (investigational/approved). Geographic exposure: Global — largest sales in U.S., substantial Europe and row markets. Market & share metrics (most recent available — see sources) Market capitalization: ~USD 642–702 billion (source dispersion; SEC shares outstanding 946.46M as of 4 Aug 2025) Shares outstanding: 946,456,759 (per 10‑Q, Aug 4, 2025) Float: ~946M (per public filings) Last close (around 26 Sep 2025): ~USD 714–742 (sources vary intraday); use USD 714.59 (MLQ / market snapshots) as reference. P/E (trailing / consensus forward): TTM P/E ~49; next‑FY consensus ~30 (see market data). EV/EBITDA (market snapshots): ~38x (site snapshots). Price performance (approx., source snapshots to 25–26 Sep 2025): 1D: -3.7%; 1M: -4% to -8% range; 3M: -10% to -15%; 1Y: down ~20% from 52‑week high (use precise values in sources below). (Notes: market figures vary by data vendor; SEC 10‑Q provides authoritative share count. All market prices quoted are approximations from public market data as of 26 Sep 2025 — see Sources.) 2) Financial results — consolidated summary (historical 3 years + last 4 quarters) Sources: Eli Lilly SEC filings (10‑K 2024, 10‑Q Jun 30 2025), company press releases, market data sites (Yahoo/MLQ/FactSet snapshots). All amounts USD. Annuals (selected items; amounts in billions except EPS in USD) 2022 (FY): Revenue ≈ 28.3; Net income ≈ 5.16; Diluted EPS ≈ 5.41; FCF ≈ 8.0 (approx). 2023 (FY): Revenue ≈ 40.5; Net income ≈ 11.0; Diluted EPS ≈ 12.99; FCF ≈ 11.5. 2024 (FY): Revenue ≈ 45.0; Net income ≈ 10.6; Diluted EPS ≈ ~12.00; FCF ≈ ~12.0. (Notes: 2023–2024 saw large revenue step from GLP‑1 products; numbers approximated from company reports and market summaries—see Sources for exact line items.) Most recent four quarters (approx, Q3 2024 – Q2 2025) Q3 2024: Revenue ≈ 9.5B; Net income ≈ 2.2B; EPS diluted ≈ 2.32 Q4 2024: Revenue ≈ 11.0B; Net income ≈ 2.6B; EPS ≈ 2.73 Q1 2025: Revenue ≈ 14.0B; Net income ≈ 3.8B; EPS ≈ 4.2 Q2 2025: Revenue = 15.56B (company release Aug 7, 2025); Net income ≈ 4.9B; EPS (reported) ≈ 6.31 (last quarter’s EPS per consensus/press) YoY growth / trends (high level) Revenue CAGR (2022–2024): ~30–35% driven by Mounjaro/Zepbound launch adoption and price/volume mix. Net income: large increase 2022→2023; 2024 flattening due to investments, higher operating costs and mix. Q1–Q2 2025 continue strong growth. Margins: Operating margin expanded materially vs pre‑GLP era; recent operating margin ~35–38% (site snapshots). Net margin ~23–25%. Tabular snapshot Table: (Year | Revenue | Net income | Diluted EPS | FCF) 2022 | 28.3B | 5.2B | 5.41 | ~8.0B 2023 | 40.5B | 11.0B | 12.99 | ~11.5B 2024 | 45.0B | 10.6B | ~12.0 | ~12.0B Last 4Q (sum) 2024Q3–2025Q2 | ~50.1B | ~14.5B | (trailing EPS approx) 3) Balance sheet & liquidity (latest quarter Jun 30, 2025 unless noted) Key items (USD, rounded) Cash & equivalents: ~3.1–3.4B (per June 30, 2025 XBRL snippet) Current assets: (per 10‑Q) — refer to consolidated balance sheet; working capital positive. Total debt: ~38–40B (notes due 2026/2030; total debt around $39.9B per market snapshot) Net debt: ~36B (total debt minus cash) Ratios (approx) Current ratio: ~1.15 Quick ratio: ~0.89 Debt/Equity: vendor snapshots differ; leverage measured as Debt/Total Capital moderate given high cash flow (Total Debt/Enterprise Value small % per some snapshots). Commentary on solvency/liquidity Strong operating cash generation and large market cap provide ample capacity to service debt and fund capex/R&D. Short‑term liquidity adequate; interest coverage is strong given high EBITDA and cash flow. Material execution risk arises if GLP‑1 pricing or demand deteriorates sharply—could stress near‑term growth assumptions but balance sheet remains investment grade in profile. 4) Cash flow (latest 4 quarters, approximate) Operating cash flow (TTM): ~17–18B Capital expenditures (TTM): ~1.5–2.0B (increased manufacturing capex in 2024–2025) Free cash flow (TTM): ~15–16B Commentary Cash generation is robust and supports capex, share repurchases and dividend; capex is elevated for capacity expansion but remains a modest share of operating cash flow. FCF margin is strong and sustainable if product demand persists. 5) Comparable valuation (peers) — snapshot multiples Peers chosen: Novo Nordisk (NVO), AstraZeneca (AZN), Amgen (AMGN), Regeneron (REGN) — peer set focused on diabetes/biotech large caps. Table (approximate multiples — market data as of 26 Sep 2025) LLY: P/E ~49 (TTM), EV/EBITDA ~38, P/S ~15 NVO: P/E ~35, EV/EBITDA ~28, P/S ~10 AMGN: P/E ~20, EV/EBITDA ~12, P/S ~4 REGN: P/E ~25, EV/EBITDA ~15, P/S ~6 Comment: LLY trades at premium to large pharm/biotech peers reflecting superior growth from GLP‑1 franchises and margin profile; premium justified only if growth and pricing hold. 6) Fair value estimate — Simplified DCF (base case) Assumptions Base year unlevered free cash flow (FCF) = USD 15.5B (TTM approximate). Explicit forecast horizon = 5 years. FCF growth: Year1–2: +10% then Year3: +8%, Year4: +6%, Year5: +4% (reflecting moderation as market saturates and competition intensifies). Terminal growth rate = 3.0% (long‑term GDP/inflation real+inflation). WACC = 8.5% (reflects large cap pharma, low beta, moderate leverage). Calculation (rounded) Projected FCFs: Year1: 17.05B; Year2: 18.76B; Year3: 20.26B; Year4: 21.48B; Year5: 22.34B Terminal value at end Year5 = Year5*(1+g)/(WACC−g) = 22.34*(1.03)/(0.085−0.03) ≈ 22.34*1.03/0.055 ≈ 418.5B Discount PV of FCFs + terminal (discounted at 8.5%) ≈ PV(FCFs) ~ (sum PV FCFs) ≈ 72–80B + PV(Terminal) ≈ 300–330B → Enterprise value ~380–410B. Net debt (~36B) → implied equity value ≈ 344–374B. Divide by shares outstanding (946.5M) → implied fair price ≈ USD 363–395 per share. Observation: The simplified DCF produces a materially lower fair value than market cap — this stems from conservative growth fade and relatively low WACC; however market prices imply much higher expectations (market cap ~650–700B). Discrepancy suggests market pricing embeds either higher sustained FCF growth, lower discount rate, or different terminal assumptions. Because LLY’s current market cap and observed multiples are much higher, applying market‑implied expectations leads to a higher implied fair value (consistent with P/E ~49). For investors, using the simplified DCF above suggests the stock may be fully valued or richly priced unless strong multi‑year growth persists. Sensitivity WACC ±1% (7.5% / 9.5%) with base growth: implied price range roughly USD 470 (WACC 7.5%) to USD 295 (WACC 9.5%). Terminal growth ±1% (2% / 4%): price moves roughly USD −60 / +90 vs base. (Notes: DCF is simplified and uses rounded FCF; full model should use operating projections by product, tax, capex schedule. If instead one applies market multiples to 2026E EBITDA, implied prices vary widely — see sources.) 7) SWOT Strengths Market leader in next‑gen GLP‑1/dual agonists (rapid adoption). Strong gross & operating margins; robust FCF generation. Diversified pipeline (oncology, CV) and global commercial footprint. Experienced management, strong manufacturing investment. Weaknesses High valuation multiples implying little margin for error. Dependence on a few high‑revenue products (Mounjaro/Zepbound). Manufacturing scale‑up challenges and supply chain concentration risks. Increasing SG&A/R&D investment could press short‑term margins. Opportunities New indications (cardio‑protective label for tirzepatide), oral incretins (orforglipron) could expand market. International expansion and formulary wins. Bolt‑on M&A to diversify revenue streams. Threats Intense competition (Novo Nordisk market share, formulary dynamics). Payer reimbursements, pricing caps, regulatory scrutiny. Potential adverse trial/regulatory outcomes for pipeline assets. Macroeconomic/tighter capital markets affecting healthcare spend. 8) Key risks, catalysts & timeline Primary risks Competitive pressure from Novo Nordisk (Wegovy/Ozempic), payer formulary preferences (e.g., CVS formulary moves). Regulatory/pricing risk (US and international). Execution: supply chain, manufacturing scale, and successful indication expansions. Concentration risk: heavy revenue share from GLP‑1 franchise. Near‑term catalysts & timeline (next 12 months approximate) Q3 2025 earnings release (expected Oct–Nov 2025; company calendar/earnings dates per IR). FDA/regulatory milestones for label expansions / approvals for oral incretins or oncology programs (dates vary; watch company pipeline calendar). Quarterly sales updates and guidance adjustments — next: Q3 2025 release. (Precise dates: refer to investor relations events page and SEC filings; earnings typically quarterly — check IR for confirmed dates.) 9) Recommendation & risk positioning Recommendation: Hold, with possible "Buy the Dip" scenario. Rationale: Strong fundamentals and cash generation support a positive long‑term outlook, but the stock trades at elevated multiples that already price in sustained high growth; meaningful execution/competitive downside could compress the valuation. Hold for investors with neutral risk appetite; consider trimming positions for valuation‑sensitive portfolios and adding on material pullbacks or clearer evidence of sustained mid‑teens revenue growth beyond 2026. Suggested horizon: Medium term (12–24 months) for monitoring catalysts; long term (3–5 years) only if comfortable with pipeline and competitive dynamics. Risk/return profile: Medium risk / moderate to high reward conditional on continued GLP‑1 dominance and successful pipeline commercialization; downside risk if market share or pricing erodes. 10) Sources & data date Primary sources used (data current through 26 Sep 2025): Eli Lilly & Company SEC filings: Form 10‑Q for quarter ended June 30, 2025 (SEC.gov). Eli Lilly Q2 2025 results press release (Aug 7, 2025) and investor presentations (company IR). Market data snapshots and summaries: MLQ.ai, Yahoo Finance, Fox Business / FactSet quotes (price, multiples, market cap, performance snapshots). News: Yahoo Finance, PR Newswire coverage of Q2 2025 results.
NYSE:LLYLong
by dPEngineering
Eli Lilly: Weight-Loss Giant Amid AI Drug Discovery Eli Lilly: Undervalued Weight-Loss Giant Amid AI Drug Discovery and Virginia Jobs Boom Trends? $1050 Target in Sight? Eli Lilly (LLY) shares are trading at $755.39 today, up 0.45% amid analyst upgrades and fresh headlines on its $2.3 billion Virginia manufacturing plant expansion, creating 650 high-paying jobs in Goochland County. This comes as Q2 2025 earnings showcased 36% revenue growth to $11.3B, driven by blockbuster obesity drugs like Mounjaro and Zepbound, with analysts forecasting 2025 EPS of $13.14—up 20% YoY. Just as #AI and #technology explode on X with 17K+ mentions today (fueled by AI video generators and drug discovery hype), and #business trends spotlight corporate expansions like Eli Lilly's Virginia move, LLY's AI-powered R&D pipeline positions it for viral growth in the $100B+ weight-loss market. But with a forward P/E of 28x, is LLY the undervalued pharma powerhouse ready for a rally to $1050, or will patent cliffs and competition temper the upside? Let's break down the fundamentals, SWOT, charts, and setups for September 17, 2025. Fundamental Analysis Eli Lilly's momentum is anchored in its GLP-1 dominance and innovative pipeline, with the Virginia plant bolstering U.S. production amid supply constraints for weight-loss drugs. Analysts expect 2025 revenue of $47.3B (up 18% YoY), powered by approvals for oral obesity pills and oncology breakthroughs like Verzenio. With #AI trends surging on X, LLY's use of machine learning in drug design (e.g., accelerating lung cancer therapies) undervalues its tech edge, trading 18% below fair value per DCF models. However, regulatory hurdles for new GLP-1s could delay peaks if biosimilar competition ramps up. - **Positive:** - Virginia plant announcement drives job creation buzz, aligning with #business trends and signaling supply chain resilience for 20%+ EPS growth. - Q2 beat with $2.9B in Mounjaro sales; AI integrations in R&D tie into today's #AI hype, projecting $100B+ peak sales for obesity franchise. - Broader trends in personalized medicine and #technology (19K mentions) position LLY for 15% annual revenue CAGR amid global demand. - **Negative:** - Patent expirations on key drugs like Humalog loom by 2026, clashing with #AI optimism if innovation lags. - High R&D spend ($10B+ annually) pressures margins if trial delays hit, especially in a sticky inflation environment. SWOT Analysis **Strengths:** Market-leading GLP-1 portfolio with 50%+ share in obesity treatments; robust cash flow ($12B FCF TTM) funds AI-driven innovations, amplified by #AI relevance in drug discovery. **Weaknesses:** Premium valuation at 28x forward P/E amid growth dependency; supply bottlenecks exposed by demand surges, vulnerable in #technology-shifting markets. **Opportunities:** Virginia expansion for 650 jobs taps #business trends; AI for faster trials unlocks $50B+ in new therapies, undervalued at 18% below fair value amid #AI boom. **Threats:** Biosimilar erosion from Novo Nordisk rivals; regulatory scrutiny on weight-loss ads during viral #technology discussions on social media. Technical Analysis On the daily chart, LLY is in a bullish uptrend, coiling in an ascending channel after bouncing from $740 support, with volume rising on plant news and mirroring #AI volatility spikes. The weekly confirms a multi-year bull flag from 2023 lows, now extending higher. Current price: $755.39, with VWAP at $752 as intraday pivot. Key indicators: - **RSI (14-day):** At 72, overbought but strong positive momentum—watch for pullback amid #technology surges. 📈 - **MACD:** Bullish crossover with expanding histogram, signaling acceleration; no divergence yet. ⚠️ - **Moving Averages:** Price above 21-day EMA ($745) and 50-day SMA ($730), golden cross intact for medium-term bull. Support/Resistance: Key support at $740 (recent low and 50-day SMA), resistance at $770 (September high) and $800 (analyst target). Patterns/Momentum: Channel breakout targets $850; strong buy signals. 🟢 Bullish signals: Volume on #business news. 🔴 Bearish risks: RSI overbought could retrace 5% on profit-taking. Scenarios and Risk Management - **Bullish Scenario:** Break above $770 on oral pill approval or #AI catalyst targets $850 short-term, then $1050 by year-end. Buy dips to $740 for entries tied to Virginia jobs hype. - **Bearish Scenario:** Drop below $740 eyes $700 (200-day EMA); competition news amid #technology fade could trigger 10% pullback. - **Neutral/Goldilocks:** Range-bound $740–$770 if data mixed and #AI cools, suiting options or waiting for Q3 earnings. Risk Tips: Use stops 2% below support ($725) to manage volatility. Risk 1-2% per trade. Diversify with NVO or broader healthcare to avoid #business correlation traps. Conclusion/Outlook Overall, a bullish bias if LLY holds $740, supercharged by today's #AI and #business trends, affirming its undervalued status with 30%+ upside on pipeline wins and expansions. But watch FDA updates and Q3 guidance for confirmation—this fits September's healthcare rotation amid viral tech hype. What’s your take? Bullish on LLY amid #AI drug trends or waiting for a dip? Share in the comments!
NYSE:LLYLong
by DCAChampion
LLY - Clean Levels UpdatedEli Lilly's hit those 708.49 and 711 levels I mentioned in my previous LLY post. I've added some weekly levels, and a couple relevant spots from my boxed LLY chart. If LLY loses steam up here we could easily see a retest of that box top area in the $680 - $678 range. Otherwise if we see a market wide reversion from today's liquidation, and LLY clears today's high(~714) and firmly holds that high volume area, that gap($738) fill would be a no-brainer. Personally leaning on the side of a short continuation(in the near time at least), didn't really trust the low volume float up over the last few trading days, and definitely don't like the decreasing volume into that $711 - $714 area (I'd consider it a Look above and fail). Regardless of bias, we trade what we see. ~ The Villain.
NYSE:LLYShort
by The_Villain_777
LLY - Clean LevelsBull flag patten on the LLY weekly Chart. The base of the flag/channel has been reactive so far although with low volume (See previously boxed LLY chart) off the top of the recent boxed range. If you look at the previous chart, you will see that LLY is currently floating up through a low volume node on the anchored volume profile. Unless sellers step in here, 708.49/709 - 711.44 is the next target. Volume will be in that area, if buyers step in, could be great for calls. Otherwise we could see a look above and fail of the top boxed range(again see previous chart under related publications to the right of this post). ~The Villain
NYSE:LLY
by The_Villain_777
LLY \$687.50 Call – One-Day High-Momentum Play🚀 LLY \$687.50 Call – One-Day High-Momentum Play **Sentiment:** 🟢 *Moderate Bullish* * **Call/Put Ratio:** 3.08 → strong speculative interest * **Daily RSI:** <45, rising 📈 * **Weekly RSI:** <50, rising 📈 * **Volume:** Weak (0.9× last week) → limited institutional support * **VIX:** <15 → favorable for directional calls * **Gamma Risk:** HIGH ⚡ — expiry in 1 day --- ### 📊 **Consensus Snapshot** ✅ Strong bullish options flow ⚠️ Weak volume + high gamma → cautious sizing 💡 Low volatility favors call strategy --- ### 🎯 **Trade Setup** * **Type:** CALL (Single-leg) * **Strike:** \$687.50 * **Expiry:** 2025-08-15 * **Entry:** \$0.79 * **Profit Target:** \$1.20 (+153%) * **Stop Loss:** \$0.40 (–50%) * **Confidence:** 70% * **Entry Timing:** Market open --- 💬 *High-risk, short-term expiry play — monitor closely.* 📌 *Not financial advice. DYOR.* --- **#LLY #OptionsTrading #CallOptions #DayTrading #StocksToWatch #GammaRisk #OptionsFlow #TradingSignals**
NYSE:LLYLong
by quantsignals
Eli Lilly (LLY) – Pharma Giant at a Key Price LevelHi, Eli Lilly & Co. is one of the world’s largest pharmaceutical companies, founded in 1876 and headquartered in Indianapolis. It operates in over 125 countries and is best known for blockbuster treatments in diabetes, obesity, oncology, and immunology. Recent growth has been driven largely by its GLP-1 class drugs Mounjaro and Zepbound, which have quickly become industry leaders in the weight-loss and diabetes markets. Recent Fundamentals (Q2 2025) Revenue: $15.56 B (+38% YoY) - EPS: $6.31 (beat expectations) - Mounjaro sales: $5.2 B - Zepbound sales: $3.38 B - Full-year guidance: Revenue $60–62 B, EPS $21.75–$23.00 - Margins: Gross margin ~82.6%, net margin ~25.9% - Profitability: ROE ~75.5%, ROIC ~29.6% While fundamentals remain strong, the recent Phase III data for the oral weight-loss pill orforglipron came in below expectations, sparking a ~14% drop, the stock’s steepest one-day decline in decades. Analysts have since trimmed long-term sales forecasts for this product. From a valuation perspective, the stock trades at a premium (~41× P/E, ~10.7× P/S), leaving little room for major disappointments. Technicals Technically speaking, the price has arrived in the zone where I’ve been patiently waiting to share it as an idea. This is a good area from where to start building positions if you’re interested. There are quite a few technical confluence factors aligning here, but be ready to grab it also around $500 if the market offers it. Let that be your guide: - If you’re not willing to hold long-term, don’t touch it. - If you’re not willing to buy more at lower prices, don’t touch it. Good luck, Vaido
NYSE:LLYLong
by VaidoVeek
ELI LILLY Is starting its next big rally.Eli Lilly (LLY) is about to test its 1W MA50 (blue trend-line) following a rebound just below the 1W MA100 (green trend-line). The latter, has been the ultimate market Support since May 2018 (last time it broke below it). The overall correction since the July 15 2024 High seems like a Bull Flag pattern, no different than all the others after 2018 which only served as healthy rebalancing of an overbought price action. Based on he 1W RSI in particular and the Bullish Divergence it displayed, the current Bull Flag resembles more the March - October 2019 pattern. Both that and the next one reached their 2.0 Fibonacci extensions. As a result, our long-term Target on LLY is just below the 2.0 Fib at $1300. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
2
Can Lilly Redefine Weight Loss Market Leadership?Eli Lilly is rapidly emerging as a dominant force in the burgeoning weight loss drug market, presenting a significant challenge to incumbent leader Novo Nordisk. Lilly has demonstrated remarkable commercial success despite its key therapy, Zepbound (tirzepatide), entering the market well after Novo Nordisk's Wegovy (semaglutide). Zepbound's substantial revenue in 2024 underscores its rapid adoption and strong competitive standing, leading market analysts to project Eli Lilly's obesity drug sales will surpass Novo Nordisk's within the next few years. This swift ascent highlights the impact of a highly effective product in a market with immense unmet demand. The success of Eli Lilly's tirzepatide, the active ingredient in both Zepbound and the diabetes treatment Mounjaro, stems from its dual mechanism targeting GLP-1 and GIP receptors, offering potentially enhanced clinical benefits. The company's market position was further solidified by a recent U.S. federal court ruling that upheld the FDA's decision to remove tirzepatide from the drug shortage list. This legal victory effectively halts compounding pharmacies from producing unauthorized, cheaper versions of Zepbound and Mounjaro, thereby protecting Lilly's market exclusivity and ensuring the integrity of the supply chain for the approved product. Looking ahead, Eli Lilly's pipeline includes the promising oral GLP-1 receptor agonist, orforglipron. Positive Phase 3 trial results indicate its potential as a convenient, non-injectable alternative with comparable efficacy to existing therapies. As a small molecule, orforglipron offers potential advantages in manufacturing scalability and cost, which could significantly expand access globally if approved. Eli Lilly is actively increasing its manufacturing capacity to meet anticipated demand for its incretin therapies, positioning itself to capitalize on the vast and growing global market for weight management solutions.
NYSE:LLYLong
by UDIS_View
Eli Lilly (LLY) Shares Fall Over 15% in MayEli Lilly (LLY) Shares Fall Over 15% in May The share price of Eli Lilly and Company (LLY), the world’s largest pharmaceutical company, has seen a sharp shift in market sentiment: → From its April low to high, LLY shares rose by over 30%; → However, since the start of May, the LLY stock price has dropped more than 15% — the closing price on the last trading day of April was around $895, while today the share is trading near $775. Why Are Eli Lilly (LLY) Shares Falling? The decline can be attributed to three key factors: 1→ Q1 Earnings Report: Although the company reported earnings per share above expectations ($3.34 vs $3.25), investors may have been concerned by significantly higher spending on research and development. 2→ Competitor Partnership: CVS Health’s announcement that it will offer Novo Nordisk’s Wegovy instead of Lilly’s Zepbound added further pressure to LLY shares. 3→ Sector Sentiment: Broader biotech sentiment turned negative following reports that the Trump administration is considering a pricing model that would cap drug prices based on lower rates in other countries. The media is also discussing upcoming decisions from Vinay Prasad, the new head of the FDA division overseeing vaccines and gene therapy. Technical Analysis: Eli Lilly (LLY) Share Chart Key price movements (marked on the chart) justify the formation of a downward channel. On the one hand, bearish sentiment may intensify in light of recent developments. The median line of the channel could act as resistance to any upward movement. On the other hand, bulls may find support around the $765 level — a former resistance point and the boundary between two price gaps. This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
NYSE:LLY
by FXOpen
Eli Lilly: Catch the Knife or Wait for Support?LLY Just Dropped — Opportunity or Trap? 🔥 LLY (Eli Lilly) is on every trader’s radar! With biotech momentum and blockbuster drug potential, this stock is ready to rip once the dust settles. Smart money is eyeing key zones for a golden entry. 💊📈 📉 New Entry Zones: 🔥 630.00 – Solid buy level 🔥 550.00 – Strong value zone 🔥 465.00 – Deep discount opportunity (load-up zone!) 🎯 Profit Targets: ✅ 730.00 📈 (First leg up) ✅ 800.00 🚀 (Breakout zone) ✅ 900.00+ 💰 (All-time high chase) 💡 Volatility creates opportunity. LLY is a beast in the pharma game—any dip could set up a powerful bounce. Watch for heavy accumulation and reversal signals near those buy zones! 🚀 Ready to ride the next wave? LLY’s runway is long and the upside is juicy! #LLY #PharmaStocks #BuyTheDip #GrowthPlays 📌 Disclaimer: Not financial advice. Do your own research and consult with a professional before investing. 🔎💼
NYSE:LLYLong
by Robert_V12
ELI LILLY: The time to buy and target 1,300 is now.Eli Lilly is neutral on its 1D technical outlook (RSI = 48.409, MACD = -5.160, ADX = 28.927) and this is technically the most efficient level to buy for the long term towards the end of the year, as the price is sitting around its 1W MA50. The macro pattern is a Channel Up starting back in March 2019 and every time this broke under the 1W MA50 (but remained supported above the 1W MA100) and consolidated, it was the most efficient long term buy signal. In 6 years this has only happened 4 times and all those times the 1W RSI hit the 38.750 S1 level. The immediate target of all bullish waves that started after such bottoms, has been the 2.0 Fibonacci extension. Go long, TP = 1,300. ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:LLYLong
by InvestingScope
The Next Big Healthcare Stock?The chart for VERV shows a prolonged downtrend since mid-2021, with multiple resistance trendlines capping price action. However, the stock is now testing a potential breakout above these trendlines and the 50-week EMA (green line), which has acted as dynamic resistance. The RSI is rising above 60, signaling increasing bullish momentum, and the latest weekly candle, up 11.28%, suggests growing buying interest. If VERV successfully holds above this breakout zone, it could push toward the $10-$15 resistance range, confirming a trend shift. However, failure to sustain above the 50EMA could result in another rejection, reinforcing the downtrend. Volume is picking up, adding weight to the bullish case, but confirmation above key levels remains crucial for a sustained move higher. Disclaimer: This analysis is for educational purposes only and should not be considered financial advice. Trading and investing involve risk, and independent research or consultation with a professional is recommended before making any financial decisions.
VLong
by MysticMads
ELI LILLY ahead of a 1D Golden Cross targeting $1225Last time we looked at Eli Lilly (LLY) 3 months ago (November 21 2024, see chart below), we've identified the bottom of its 5-year Channel Up and issued a strong long-term buy signal: Now we are upgrading our Target as the price action turned out to be very similar to the 2nd half of 2020, at the end of which the company witnessed strong growth. As you can see both 2020 and 2024 patterns have been correction phases in the form of Channel Downs. Even their 1D RSI sequences are similar. A 1D Death Cross paved the way for the bottom soon after and a 1D Golden Cross (Jan 11 2021) confirmed the start of a new phase of growth. The price is now above the 1D MA200 (orange trend-line) and if it continues to replicate 2021, then we expect this to be a Bullish Leg that will target the 1.786 Fibonacci extension. Our long-term Target now goes from $1135 to $1225. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
Halftime Report: LLY Up From Here? Hold for better PriceWe've been watching LLY after Open this morning allowed it to bounce up to $783.63. It has since settled on the 50% Retracement on the 5 Minute, which we were looking for it to break down back to at least the $765-$766 Price Range, looking to get in around $765.45specifically. With a Price Target $775 (Short-Term Trade Target) on the rebound and retest. We're looking at a stop around $761.97 to be safe in case it comes down hard and surpasses our entry. On a longer-time frame, we're looking for potential a $780.65 - $785 retest. Stay tuned by connecting at the website in our signature! We deliver this and more financial tools to make life that much easier on You! - @MyMIWallet #MyMIWallet
NYSE:LLYLong
by MyMIWallet
LLY 1H Swing Long Aggressive Trend TradeAggressive Trend Trade - short impulse + volumed TE / T1 + support level + biggest volume Sp + weak test + first bullish bar close entry Calculated affordable stop limit 1 to 2 R/R take profit Daily Context "+ long impulse + 1/2 correction - expanding T2 + support level + volumed manipulation" Monthly Context "+ long impulse + 1/2 correction + T2 level + support level - biggest volume manipulation" Yearly Context "+ long impulse - neutral zone"
NYSE:LLYLong
by MishaSuvorov
Why Buy LLY?A textbook spike trade... that's why! Every morning the stock market open gives us opening volatility spikes on the first 30 minute bar. Most are noise but when that rare one comes along that fits my rules AND has multiple matching confluences... it's time to "Strike at the Spike!" This setup has going for it: At a 50% Retracement of the recent trend (from November 18 - December 4) At the top of a Gap Level At the Volume Profile Point-of-Control for the last year of price action (see below) With a Spike that my indicator shows >80% ATR Clearance I consider the baseline for a trade; this one is 150% so it definitely fits the rules. I would take a spike if there were only 2 of those matching levels above. Targeting the local high for the first take profit at 834. Here is the Daily chart for just how key this level is: Full disclosure: NYSE:LLY is and has been one of my biggest holdings; having owned the stock for over a decade.
NYSE:LLYLong
by norok